# Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

> **NCT01142232** · PHASE1,PHASE2 · COMPLETED · sponsor: **Attaya Suvannasankha** · enrollment: 60 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide plus Melphalan during autologous stem cell transplantation
- **DRUG:** Lenalidomide maintenance

## Key facts

- **NCT ID:** NCT01142232
- **Lead sponsor:** Attaya Suvannasankha
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-27
- **Primary completion:** 2015-11-06
- **Final completion:** 2019-05-18
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142232, "Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01142232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*